Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
210 JPY | +3.45% | +1.94% | -6.25% |
Summary
- According to Refinitiv, the company's ESG score for its industry is poor.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The company appears to be poorly valued given its net asset value.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- For the past twelve months, EPS forecast has been revised upwards.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- With an enterprise value anticipated at 4.86 times the sales for the current fiscal year, the company turns out to be overvalued.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-6.25% | 274M | D+ | ||
+17.18% | 83.07B | C+ | ||
-28.48% | 70.89B | B- | ||
+5.28% | 28.32B | C+ | ||
-7.44% | 17.73B | B | ||
+1.60% | 17.43B | A- | ||
+2.10% | 15.64B | A- | ||
+7.02% | 13.46B | B- | ||
+64.96% | 12.69B | C- | ||
+6.80% | 12.82B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 7779 Stock
- Ratings CYBERDYNE Inc.